0001213900-22-049677.txt : 20220819 0001213900-22-049677.hdr.sgml : 20220819 20220819160124 ACCESSION NUMBER: 0001213900-22-049677 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220815 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220819 DATE AS OF CHANGE: 20220819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Emmaus Life Sciences, Inc. CENTRAL INDEX KEY: 0000822370 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870419387 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35527 FILM NUMBER: 221180727 BUSINESS ADDRESS: STREET 1: 21250 HAWTHORNE BOULEVARD, SUITE 800 CITY: TORRANCE STATE: CA ZIP: 90503 BUSINESS PHONE: 310-214-0065 MAIL ADDRESS: STREET 1: 21250 HAWTHORNE BOULEVARD, SUITE 800 CITY: TORRANCE STATE: CA ZIP: 90503 FORMER COMPANY: FORMER CONFORMED NAME: MYnd Analytics, Inc. DATE OF NAME CHANGE: 20151211 FORMER COMPANY: FORMER CONFORMED NAME: CNS RESPONSE, INC. DATE OF NAME CHANGE: 20070313 FORMER COMPANY: FORMER CONFORMED NAME: STRATIVATION, INC. DATE OF NAME CHANGE: 20051115 8-K 1 ea164601-8k_emmauslife.htm CURRENT REPORT
0000822370 false 0000822370 2022-08-15 2022-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 15, 2022

 

Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35527   87-0419387

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

21250 Hawthorne Boulevard, Suite 800, Torrance, CA   90503
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (310) 214-0065

 

 

(Former name or former address, if changed, since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading Symbol   Name of each exchange on which registered
None        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Related-Party Loan

 

On August 16, 2022, Yutaka Niihara, M.D., M.P.H., the Chairman of the Board and Chief Executive Officer of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) and his wife loaned the company $1,576,574, representing the net proceeds of personal loans to them from unaffiliated third parties in the principal amount of $1,668,751, as well as $250,000 from personal funds. In exchange for the loans, we issued to Dr. and Mrs. Niihara separate promissory notes in the principal amounts of $1,668,751 and $250,000, respectively, which are due and payable in a lump sum on maturity on August 16, 2027 and bear interest at the rate of 10% per annum, payable monthly in arrears. The foregoing loans were in addition to a $50,000 loan to us from Hope International Hospice, Inc., an affiliate of Dr. and Mrs. Niihara, on August 15, 2022, which is evidenced by a demand promissory note of the company bearing interest at the rate of 10% per annum. The proceeds of the loans will be used to prepay $1,924,819 of outstanding third-party indebtedness of the company.

 

The foregoing description is a summary only of the material terms of the loans and is qualified by reference to the promissory notes evidencing the loans, copies of which are included as Exhibits 10.1 – 10.3 to this Current Report and incorporated herein by reference. The loans are the most recent of a number of related-party loans previously reported in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2021 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, respectively. The foregoing description of the loans should be read in conjunction with such Annual and Quarterly Reports, including the financial statements contained therein and the discussions under the captions “Risk Factors” and “Management’s Discussion of Financial Condition and Results of Operation.” 

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information in the first paragraph of Item 1.01 of this Current Report is hereby incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

See the accompanying Index to Exhibits, which information is incorporated herein by reference.

 

1 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 19, 2022 Emmaus Life Sciences, Inc.
     
  By: /s/ YASUSHI NAGASAKI
    Name:  Yasushi Nagasaki
    Title: Chief Financial Officer

 

2 

 

 

INDEX TO EXHIBITS

 

Exhibit Number   Description
     
10.1   Promissory Note dated August 16, 2022 in the principal amount of $1,668,751 in favor of Yutaka and Soomi Niihara.
     
10.2   Promissory Note dated August 16, 2022 in the principal amount of $250,000 in favor of Yutaka and Soomi Niihara.
     
10.3   Promissory Note dated August 15, 2022 in the principal amount of $50,000 in favor of Hope International Hospice, Inc.
     
104   Cover Page Interactive Date File (embedded within Inline XBRL document)

 

 

3

 

 EX-10.1 2 ea164601ex10-1_emmauslife.htm PROMISSORY NOTE DATED AUGUST 16, 2022 IN THE PRINCIPAL AMOUNT OF $1,668,751 IN FAVOR OF YUTAKA AND SOOMI NIIHARA.

Exhibit 10.1

 

EXHIBIT A TO UNANIMOUS WRITTEN CONSENT

 

EMMAUS LIFE SCIENCES, INC.

Promissory Note

 

Principal Amount:  $1,668,751.00 Loan Date: August 16, 2022
   
Interest Rate:  10% per year Loan Due Date: August 16, 2027
   
Lender:  Yutaka and Soomi Niihara  

 

Address for Payment:

 

FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (“Borrower”), agrees to pay to Lender or his or her registered assigns (the “Holder”) the Principal Amount, together with accrued interest at the stated Interest Rate, on the following terms of this Promissory Note (this “Note”).

 

Terms of Repayment: Simple interest at the stated Interest Rate will accrue on the outstanding Principal Amount hereof commencing on the stated Loan Date until this Note is paid in full. Accrued interest shall be payable monthly on or before the last day of each month. The entire unpaid Principal Amount hereof and accrued and unpaid interest hereon shall become immediately due and payable upon the stated Loan Due Date.

 

2. Prepayment: This Note may be prepaid in whole or in part at any time after the Loan Date without premium or penalty. All prepayments shall first be applied to accrued interest and then to principal.

 

3. Place of Payment: All payments due under this Note shall be made by check of Borrower sent to the Lender’s address set forth above, or at such other place as the Holder may designate in writing to Borrower. At Borrower’s request, the Holder shall furnish Borrower with the Holder’s taxpayer ID number or Social Security number to facilitate the Borrower’s tax reporting.

 

4. Default: In the event of default hereunder, Borrower agrees to pay all costs and expenses, including reasonable attorney’s fees, incurred by the Holder in connection therewith.

 

5. Acceleration of Debt: If Borrower (i) fails to make any payment due under the terms of this Note or seeks relief under the U.S. Bankruptcy Code, (ii) suffers an involuntary petition in bankruptcy or receivership that is not vacated within 60 days, (iii) consents to the appointment of a receiver, trustee, assignee, liquidator or similar official or such appointment is not discharged or stayed within 60 days, (iv) makes a general assignment for the benefit of its creditors or (v) admits in writing that it is generally unable to pay its debts as they become due, the entire outstanding Principal Amount and any accrued and unpaid interest hereon shall be immediately due and payable to the Holder upon demand therefor by Lender.

 

 

 

 

6. Modification: No modification or waiver of any of the terms of this Note shall be effective unless set forth in a writing signed by Borrower and the Holder. No waiver of any breach or default hereunder shall be deemed a waiver of any subsequent breach or default of the same or similar nature.

 

7. Complete Note: This Note is the complete and exclusive statement of agreement of the parties with respect to the subject matter hereof. This Note replaces and supersedes all prior written or oral agreements or statements by and among the parties with respect to the same subject matter. No representation, statement, condition or warranty is made by the parties in connection with this Note except as expressly set forth herein.

 

8. Transfer of the Note: This Note may be transferred, in whole or in part, at any time or from time to time, by the Lender upon surrender of this Note to Borrower, whereupon the Borrower will forthwith issue and deliver a new Note registered as the Holder may request, representing the outstanding Principal Amount hereof being transferred and, if less than the entire outstanding Principal Amount is being transferred, a new Note to the Holder representing the outstanding Principal Amount not being transferred. Prior to due presentment for transfer to Borrower of this Note, Borrower and its agents may treat the Holder in whose name this Note is duly registered on Borrower’s books and records as the owner hereof for the purpose of receiving payment as herein provided and for all other purposes, whether or not this Note is overdue, and neither Borrower nor any such agent shall be affected by notice to the contrary.

 

9. Lost, Stolen or Mutilated Note: Upon receipt by Borrower of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note, and, in the case of loss, theft or destruction, a written undertaking by the Holder in customary form and content to indemnify Borrower and, in the case of mutilation, upon surrender and cancellation of this Note, the Borrower shall execute and deliver to the Holder a new promissory note of like tenor representing the outstanding Principal Amount hereof and accrued and unpaid interest hereon.

 

10. Severability of Provisions: If any provision of this Note is deemed unenforceable, all other provisions of this Note shall remain in full force and effect.

 

11. Choice of Law: This Note shall be construed and interpreted under the internal laws of California without regard to conflict of law principles.

 

(Signature Page Follows)

 

2

 

 

Signed this 16th day of August 2022.  
   
Emmaus Life Sciences, Inc.  
     
By: 

/s/ WILLIS C. LEE

  
  Willis C. Lee, Chief Operating Officer  

 

 

3

 

 EX-10.2 3 ea164601ex10-2_emmauslife.htm PROMISSORY NOTE DATED AUGUST 16, 2022 IN THE PRINCIPAL AMOUNT OF $250,000 IN FAVOR OF YUTAKA AND SOOMI NIIHARA.

Exhibit 10.2

 

EXHIBIT A TO UNANIMOUS WRITTEN CONSENT

 

EMMAUS LIFE SCIENCES, INC.

Promissory Note

 

Principal Amount: $250,000.00 Loan Date: August 16, 2022
   
Interest Rate: 10% per year Loan Due Date: August 16, 2027
   
Lender: Yutaka and Soomi Niihara  

 

Address for Payment:

 

FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (“Borrower”), agrees to pay to Lender or his or her registered assigns (the “Holder”) the Principal Amount, together with accrued interest at the stated Interest Rate, on the following terms of this Promissory Note (this “Note”).

 

Terms of Repayment: Simple interest at the stated Interest Rate will accrue on the outstanding Principal Amount hereof commencing on the stated Loan Date until this Note is paid in full. Accrued interest shall be payable monthly on or before the last day of each month. The entire unpaid Principal Amount hereof and accrued and unpaid interest hereon shall become immediately due and payable upon the stated Loan Due Date.

 

2. Prepayment: This Note may be prepaid in whole or in part at any time after the Loan Date without premium or penalty. All prepayments shall first be applied to accrued interest and then to principal.

 

3. Place of Payment: All payments due under this Note shall be made by check of Borrower sent to the Lender’s address set forth above, or at such other place as the Holder may designate in writing to Borrower. At Borrower’s request, the Holder shall furnish Borrower with the Holder’s taxpayer ID number or Social Security number to facilitate the Borrower’s tax reporting.

 

4. Default: In the event of default hereunder, Borrower agrees to pay all costs and expenses, including reasonable attorney’s fees, incurred by the Holder in connection therewith.

 

5. Acceleration of Debt: If Borrower (i) fails to make any payment due under the terms of this Note or seeks relief under the U.S. Bankruptcy Code, (ii) suffers an involuntary petition in bankruptcy or receivership that is not vacated within 60 days, (iii) consents to the appointment of a receiver, trustee, assignee, liquidator or similar official or such appointment is not discharged or stayed within 60 days, (iv) makes a general assignment for the benefit of its creditors or (v) admits in writing that it is generally unable to pay its debts as they become due, the entire outstanding Principal Amount and any accrued and unpaid interest hereon shall be immediately due and payable to the Holder upon demand therefor by Lender.

 

 

6. Modification: No modification or waiver of any of the terms of this Note shall be effective unless set forth in a writing signed by Borrower and the Holder. No waiver of any breach or default hereunder shall be deemed a waiver of any subsequent breach or default of the same or similar nature.

 

7. Complete Note: This Note is the complete and exclusive statement of agreement of the parties with respect to the subject matter hereof. This Note replaces and supersedes all prior written or oral agreements or statements by and among the parties with respect to the same subject matter. No representation, statement, condition or warranty is made by the parties in connection with this Note except as expressly set forth herein.

 

8. Transfer of the Note: This Note may be transferred, in whole or in part, at any time or from time to time, by the Lender upon surrender of this Note to Borrower, whereupon the Borrower will forthwith issue and deliver a new Note registered as the Holder may request, representing the outstanding Principal Amount hereof being transferred and, if less than the entire outstanding Principal Amount is being transferred, a new Note to the Holder representing the outstanding Principal Amount not being transferred. Prior to due presentment for transfer to Borrower of this Note, Borrower and its agents may treat the Holder in whose name this Note is duly registered on Borrower’s books and records as the owner hereof for the purpose of receiving payment as herein provided and for all other purposes, whether or not this Note is overdue, and neither Borrower nor any such agent shall be affected by notice to the contrary.

 

9. Lost, Stolen or Mutilated Note: Upon receipt by Borrower of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note, and, in the case of loss, theft or destruction, a written undertaking by the Holder in customary form and content to indemnify Borrower and, in the case of mutilation, upon surrender and cancellation of this Note, the Borrower shall execute and deliver to the Holder a new promissory note of like tenor representing the outstanding Principal Amount hereof and accrued and unpaid interest hereon.

 

10. Severability of Provisions: If any provision of this Note is deemed unenforceable, all other provisions of this Note shall remain in full force and effect.

 

11. Choice of Law: This Note shall be construed and interpreted under the internal laws of California without regard to conflict of law principles.

 

(Signature Page Follows)

 

2

 

Signed this 16th day of August 2022.

 

Emmaus Life Sciences, Inc.
 
By: 

/s/ WILLIS C. LEE

  
  Willis C. Lee, Chief Operating Officer  

 

 

3

 

 

 EX-10.3 4 ea164601ex10-3_emmauslife.htm PROMISSORY NOTE DATED AUGUST 15, 2022 IN THE PRINCIPAL AMOUNT OF $50,000 IN FAVOR OF HOPE INTERNATIONAL HOSPICE, INC.

Exhibit 10.3

 

EMMAUS LIFE SCIENCES, INC.

Promissory Note

 

Principal Amount: $50,000.00 Loan Date: August 15, 2022
   
Interest Rate:  10% per year Loan Due Date: On demand
   
Lender:  Hope International Hospice, Inc.  

 

Address for Payment:20705 S. Western Ave., Suite 112 Torrance, CA 90501

 

FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (“Borrower”), agrees to pay to Lender or his or her registered assigns (the “Holder”) the Principal Amount, together with accrued interest at the stated Interest Rate, on the following terms of this Promissory Note (this “Note”).

 

Terms of Repayment: Simple interest at the stated Interest Rate will accrue on the outstanding Principal Amount hereof commencing on the stated Loan Date until this Note is paid in full. The entire unpaid Principal Amount hereof and accrued and unpaid interest hereon shall become immediately due and payable upon the stated Loan Due Date.

 

2. Prepayment: This Note may be prepaid in whole or in part at any time after the Loan Date without premium or penalty. All prepayments shall first be applied to accrued interest and then to principal.

 

3. Place of Payment: All payments due under this Note shall be made by check of Borrower sent to the Lender’s address set forth above, or at such other place as the Holder may designate in writing to Borrower. At Borrower’s request, the Holder shall furnish Borrower with the Holder’s taxpayer ID number or Social Security number to facilitate the Borrower’s tax reporting.

 

4. Default: In the event of default hereunder, Borrower agrees to pay all costs and expenses, including reasonable attorney’s fees, incurred by the Holder in connection therewith.

 

5. Acceleration of Debt: If Borrower (i) fails to make any payment due under the terms of this Note or seeks relief under the U.S. Bankruptcy Code, (ii) suffers an involuntary petition in bankruptcy or receivership that is not vacated within 60 days, (iii) consents to the appointment of a receiver, trustee, assignee, liquidator or similar official or such appointment is not discharged or stayed within 60 days, (iv) makes a general assignment for the benefit of its creditors or (v) admits in writing that it is generally unable to pay its debts as they become due, the entire outstanding Principal Amount and any accrued and unpaid interest hereon shall be immediately due and payable to the Holder without demand therefor.

 

6. Modification: No modification or waiver of any of the terms of this Note shall be effective unless set forth in a writing signed by Borrower and the Holder. No waiver of any breach or default hereunder shall be deemed a waiver of any subsequent breach or default of the same or similar nature.

 

 

 

 

7. Complete Note: This Note is the complete and exclusive statement of agreement of the parties with respect to the subject matter hereof. This Note replaces and supersedes all prior written or oral agreements or statements by and among the parties with respect to the same subject matter. No representation, statement, condition or warranty is made by the parties in connection with this Note except as expressly set forth herein.

 

8. Transfer of the Note: This Note may be transferred, in whole or in part, at any time or from time to time, by the Lender upon surrender of this Note to Borrower, whereupon the Borrower will forthwith issue and deliver a new Note registered as the Holder may request, representing the outstanding Principal Amount hereof being transferred and, if less than the entire outstanding Principal Amount is being transferred, a new Note to the Holder representing the outstanding Principal Amount not being transferred. Prior to due presentment for transfer to Borrower of this Note, Borrower and its agents may treat the Holder in whose name this Note is duly registered on Borrower’s books and records as the owner hereof for the purpose of receiving payment as herein provided and for all other purposes, whether or not this Note is overdue, and neither Borrower nor any such agent shall be affected by notice to the contrary.

 

9. Lost, Stolen or Mutilated Note: Upon receipt by Borrower of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note, and, in the case of loss, theft or destruction, a written undertaking by the Holder in customary form and content to indemnify Borrower and, in the case of mutilation, upon surrender and cancellation of this Note, the Borrower shall execute and deliver to the Holder a new promissory note of like tenor representing the outstanding Principal Amount hereof and accrued and unpaid interest hereon.

 

10. Severability of Provisions: If any provision of this Note is deemed unenforceable, all other provisions of this Note shall remain in full force and effect.

 

11. Choice of Law: This Note shall be construed and interpreted under the internal laws of California without regard to conflict of law principles.

 

(Signature Page Follows)

 

2

 

 

Signed this __15th_ day of _August, _2022_  
   
Emmaus Life Sciences, Inc.  
     
By: 

/s/ WILLIS C. LEE

  
  Willis C. Lee, Chief Operating Officer  

 

 

3

 

 EX-101.SCH 5 emma-20220815.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 emma-20220815_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 emma-20220815_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Aug. 15, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 15, 2022
Entity File Number 001-35527
Entity Registrant Name Emmaus Life Sciences, Inc.
Entity Central Index Key 0000822370
Entity Tax Identification Number 87-0419387
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 21250 Hawthorne Boulevard
Entity Address, Address Line Two Suite 800
Entity Address, City or Town Torrance
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90503
City Area Code 310
Local Phone Number 214-0065
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 9 ea164601-8k_emmauslife_htm.xml IDEA: XBRL DOCUMENT 0000822370 2022-08-15 2022-08-15 iso4217:USD shares iso4217:USD shares 0000822370 false 8-K 2022-08-15 Emmaus Life Sciences, Inc. DE 001-35527 87-0419387 21250 Hawthorne Boulevard Suite 800 Torrance CA 90503 310 214-0065 false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://emmausmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea164601-8k_emmauslife.htm ea164601ex10-1_emmauslife.htm ea164601ex10-2_emmauslife.htm ea164601ex10-3_emmauslife.htm emma-20220815.xsd emma-20220815_lab.xml emma-20220815_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea164601-8k_emmauslife.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea164601-8k_emmauslife.htm" ] }, "labelLink": { "local": [ "emma-20220815_lab.xml" ] }, "presentationLink": { "local": [ "emma-20220815_pre.xml" ] }, "schema": { "local": [ "emma-20220815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "EMMA", "nsuri": "http://emmausmedical.com/20220815", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea164601-8k_emmauslife.htm", "contextRef": "From2022-08-15to2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://emmausmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea164601-8k_emmauslife.htm", "contextRef": "From2022-08-15to2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001213900-22-049677-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-049677-xbrl.zip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end